(AOF) – Abionyx (+11% to 1.27 euros) announces that it has been selected to present phase 2 clinical data from the RACERS study at the Annual Congress of the American Society of Nephrology (ASN) which will be held from November 2 to 5, 2023 in Philadelphia, Pennsylvania. In total, three abstracts dedicated to CER-001, the only recombinant human apoA-I in the world, including a Late-Breaking Abstract, were selected to be presented as a poster or orally during the Congress. Late-Breaking Poster Presentations are presentations selected by the ASN for important results from randomized clinical trials.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.